GLP1R and type 2 diabetes mellitus: Liraglutide, a GLP-1R agonist, is FDA-approved for treatment of type 2 diabetes, obesity and for secondary prevention of myocardial infarction, stroke and cardiovascular death in people with type 2 diabetes and established cardiovascular disease.